Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2025; 17(5): 103594
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.103594
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.103594
Exploring the potential function of high expression of ANAPC1 in regulating ubiquitination in hepatocellular carcinoma
Yu-Xing Tang, Wan-Ying Huang, Yi-Wu Dang, Yu-Lu Tang, Bang-Teng Chi, Yan-Ting Zhan, Gang Chen, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Wei-Zi Wu, Ji-Tian Chen, Department of Pathology, People’s Hospital of Ling Shan, Nanning 535400, Guangxi Zhuang Autonomous Region, China
Sheng-Sheng Zhou, Rong-Quan He, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Da-Tong Zeng, Department of Pathology, Redcross Hospital of Yulin City, Nanning 537000, Guangxi Zhuang Autonomous Region, China
Guang-Cai Zheng, Department of Hepatobiliary Surgery, Redcross Hospital of Yulin City, Nanning 537000, Guangxi Zhuang Autonomous Region, China
Di-Yuan Qin, Department of Computer Science and Technology, School of Computer and Electronic Information, Guangxi University, Nanning 530004, Guangxi Zhuang Autonomous Region, China
Co-first authors: Yu-Xing Tang and Wei-Zi Wu.
Co-corresponding authors: Yan-Ting Zhan and Gang Chen.
Author contributions: All authors contributed to the conception and design of this study; Zhou SS, Zheng GC, He RQ, Qin DY, Huang WY, Chen JT, Dang YW, Tang YL, Zhan YT and Chen G conceived and designed the study and guided the experimental operations; Tang YX and Wu WZ conducted the necessary experiments; Tang YX collected and analyzed the data; Tang YX, Wu WZ, Zeng DT, Chi BT drafted the manuscript; He RQ, Zhan YT and Chen G supervised the data analysis; Wu WZ, Zhou SS, Zheng GC, He RQ, Qin DY, Huang WY, Chen JT, Dang YW, Tang YL, Zhan YT and Chen G reviewed and revised the scientific content of the manuscript; All authors read and approved the final manuscript.
Supported by the National Natural Science Foundation of China, No. NSFC82160762 and No. NSFC82460783; Innovation Project of Guangxi Graduate Education, No. JGY2023068; Guangxi Higher Education Undergraduate Teaching Reform Project, No. 2022JGA146; Guangxi Zhuang Autonomous Region Health Commission Scientific Research Project, No. Z-A20220469; Future Academic Star of Guangxi Medical University, No. WLXSZX24074; and the China Undergraduate Innovation and Entrepreneurship Training Program, No. X202410598360.
Institutional review board statement: The Ethics Committee of the First Affiliated Hospital of Guangxi Medical University (No. 2022-KT-GuiWei-074), Lingshan County People’s Hospital (No. Z2090523) and the Red Cross Hospital of Yulin City (No. 2024-8) approved the study.
Institutional animal care and use committee statement: This study did not involve animal experiments.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Dataset available from the corresponding author at chengang@gxmu.edu.cn. Participants gave informed consent for data sharing.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gang Chen, MD, Professor, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. chengang@gxmu.edu.cn
Received: November 25, 2024
Revised: January 22, 2025
Accepted: March 14, 2025
Published online: May 15, 2025
Processing time: 172 Days and 0.3 Hours
Revised: January 22, 2025
Accepted: March 14, 2025
Published online: May 15, 2025
Processing time: 172 Days and 0.3 Hours
Core Tip
Core Tip: ANAPC1, a key ubiquitination regulator in tumours, remains unstudied in hepatocellular carcinoma (HCC). This first multicenter study on ANAPC1 in HCC shows its high expression in bulk RNA (n = 3913, including RNA sequencing and microarray), immunohistochemistry (n = 632) and single-cell RNA sequencing (15999 malignant hepatocytes). Clustered regularly interspaced short palindromic repeats knockout of ANAPC1 inhibited HCC cell proliferation. Gene set enrichment analysis, gene ontology and Kyoto encyclopedia of genes and genomes analyses revealed the role of the high expression of ANAPC1 in ubiquitin-mediated protein degradation, which may affect the G2/M phase and glycolysis, regulate migration inhibitory factor signalling and enhance HCC sensitivity to sorafenib, dasatinib, ibrutinib, lapatinib, nilotinib and afatinib.